Abstracts tagged "Therapy, alternative"

Abstract Number: 1010 • ACR Convergence 2021
Proton Pump Inhibitors Suppress IL-1 Mediated Carditis in a Murine Model of Kawasaki Disease
Paul Tsoukas¹, Melissa Kleinau², Lysa Langevin², Lily Morikawa³, Trang Duong¹, Suzanne Tam⁴ and Rae Yeung⁵, ¹Hospital for Sick Children, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, ON, ⁴Hospital for Sick Children, Toronto, ON, ⁵The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Kawasaki disease (KD), is the leading cause of acquired heart disease in childhood. Up to 20% of patients may develop coronary artery lesions (CAL)…
Abstract Number: 1706 • ACR Convergence 2021
Twenty-four-week Follow-up of a Randomized Controlled First-in-Human Trial of the Safety and Efficacy of Neurostimulation with a Miniaturized Vagus Nerve Stimulation Device in Patients with Multidrug-Refractory Rheumatoid Arthritis
Norman Gaylis¹, Mark Genovese², David Sikes³, Alan Kivitz⁴, Diane Horowitz⁵, Charles Peterfy⁶, Yaakov Levine⁷ and David Chernoff⁸, ¹Arthritis and Rheumatic Disease Specialties, Aventura, FL, ²Stanford University, Sunnyvale, CA, ³Florida Medical Clinic, Wesley Chapel, FL, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Northwell Health, Jericho, NY, ⁶Spire Sciences, Inc., Boca Raton, FL, ⁷SetPoint Medical, Manhassest, NY, ⁸SetPoint Medical, Sausalito, CA
Background/Purpose: Vagus nerve stimulation (VNS) activates innate neuroimmune reflexes that have been shown to reduce pro-inflammatory cytokines and clinical disease activity in subjects with rheumatoid…
Abstract Number: 1375 • ACR Convergence 2020
Remission in Axial Spondyloarthritis: Is There a Difference Between NSAIDs and Biologics in the Real Life?
Charlotte Baert¹, Charlene Mouafo Toukam², Tatiana Sokolova³, Maria S. Stoenoiu⁴, Patrick Durez⁵, Laurent Meric De Bellefon² and Adrien Nzeusseu Toukap⁶, ¹Rheumatology department, St-Luc university hospitals, Brussels, Belgium, ²Rheumatology department; St-Luc University Hospitals, Brussels, Belgium, ³Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁴1Department of Rheumatology, Cliniques Universitaires Saint-Luc, 2Institut de recherche expérimentale et cliniques (IREC), Brussels, Belgium, ⁵Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, ⁶1Department of Rheumatology, Cliniques Universitaires Saint Luc, 2Institut de recherche expérimentale et clinique (IREC), Brussels, Belgium
Background/Purpose: Randomized-controlled trials (RCTs) done in axial spondyloarthritis (AxSpA) patients have shown that remission in Ankylosing Spondylitis and nonradiographic AxSpA patients treated without biologics (BIOL)…
Abstract Number: 0373 • ACR Convergence 2020
Medical Cannabis in Ankylosing Spondylitis Following Recreational Legalization: A Prospective Cross-sectional Study
Emmanouil Rampakakis¹, Yoram Shir², John Sampalis¹, Martin Cohen², Michael Starr², Winfried Häuser³ and Mary-Ann Fitzcharles², ¹JSS Medical Research, St-Laurent, QC, Canada, ²McGill university, montreal, Canada, ³Technische Universität München, Munich, Germany
Background/Purpose: Recreational legalization of cannabis has influenced the medical use by patients. When only legal medical access was available in Canada, 4.3% of all rheumatology…
Abstract Number: 0742 • ACR Convergence 2020
Effect of IA OnabotulinumtoxinA and Vanilloids on Substance P and Neurokinin 1 Receptor Expression in the Dorsal Root Ganglia of Mice with Monoarthritis
Hollis Krug¹, Nicole Blanshan², Christopher Dorman² and Sandra Frizelle², ¹Minneapolis VAHCS and University of Minnesota Medical School, Minneapolis, MN, ²Minneapolis VAHCS, Minneapolis
Background/Purpose: Neurotoxins are increasingly being proposed as analgesics for arthritis pain. Phase II and III clinical trials have shown efficacy but with potential toxicities such…
Abstract Number: 0893 • ACR Convergence 2020
Is It Feasible to Achieve Recommended Therapeutic Target Objective in Patients with Axial Spondyloarthritis in Clinical Practice? Data from the SpA-paz Cohort
Karen Franco Gomez¹, Chaimada Plasencia-Rodriguez¹, Marta Novella Navarro¹, Diego Benavent Nunez¹, Patricia Bogas¹, Romina Nieto², Irene Monjo³, Laura Nuño¹, Alejandro Villalba⁴, Diana Peiteado¹, Alejandro Balsa-Criado¹ and Victoria Navarro-Compán⁵, ¹HOSPITAL UNIVERSITARIO LA PAZ, MADRID, Spain, ²hospital intendente carrasco, Rosario, Argentina, ³Rheumatology, La Paz University Hospital- IdiPAZ, Madrid, Spain, ⁴Hospital La Paz - IdiPAZ, Madrid, Spain, ⁵Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain
Background/Purpose: to analyze the frequency of patients with axSpA achieving maintained remission (R) or low disease activity (LDA) after receiving biological therapy. Secondary objectives included:…
Abstract Number: 0920 • ACR Convergence 2020
Machine Learning Assisted Prediction of Progression in Systemic Sclerosis Patients: An Approach to Concise, Tailored Model Construction Using Outpatient Clinical Data
Nina van Leeuwen¹, Marc Maurits², Sophie Liem², Jacopo Ciaffi², Nina Ajmone Marsan², Maarten Ninaber², Thomas Huizinga² and Jeska de Vries-Bouwstra², ¹LUMC, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Systemic Sclerosis (SSc) disease course can range from mild, to very severe with progressive organ involvement within months. Guidelines for follow-up are mainly based…
Abstract Number: 0942 • ACR Convergence 2020
Use of Medical Cannabis by Patients with Fibromyalgia: A Prospective Cross-sectional Study
Mary-Ann Fitzcharles¹, Emmanouil Rampakakis², Yoram Shir¹, John Sampalis², Martin Cohen¹, Michael Starr¹ and Winfried Häuser³, ¹McGill University, montreal, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³Technische Universität München, Munich, Germany
Background/Purpose: Treatment strategies for chronic widespread pain (CWP)/fibromyalgia (FM) are imperfect with only a modest effect from medications. Due to the many symptoms experienced by…
Abstract Number: 1136 • ACR Convergence 2020
Survey of Medical Cannabis Use in Lupus and Scleroderma
Wassim Karkache¹ and Catherine Ivory², ¹University of Ottawa, Ottawa, ON, Canada, ²University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA, Ottawa, ON, Canada
Background/Purpose: Despite the lack of research regarding medical cannabis, marijuana and its by-products have gained popularity over the last decades. A 2019 Statistics Canada report…
Abstract Number: 1220 • ACR Convergence 2020
Increased Serum Levels of Circulating Vimentin and Citrullinated Vimentin Are Differently Regulated by Tocilizumab and Methotrexate Monotherapies in Rheumatoid Arthritis
Patryk J. Drobinski¹, Anne C. Bay-Jensen², Anne S. Siebuhr³ and Morten A. Karsdal³, ¹University of Copenhagen/Nordic Bioscience, Copenhagen, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Nordic Bioscience A/S, Herlev, Denmark
Background/Purpose: Presence of citrullinated protein fragments in the circulation of patients with Rheumatoid Arthritis (RA) is a highly disease-specific phenomenon. Vimentin is often a target…
Abstract Number: 1230 • ACR Convergence 2020
Curcumin: Prevalence and Perceived Efficacy in the Treatment of Rheumatoid and Psoriatic Arthritis
Neha Bhaskar¹, Lilian Otalora Rojas², Tara Jehu¹, Shazia Beg¹ and Neha Bhanusali¹, ¹University of Central Florida College of Medicine, orlando, ²University of Central Florida HCA Healthcare GME, Orlando
Background/Purpose: Ancient Eastern medicine has valued the Curcuma longa (turmeric) plant for its powerful medicinal properties. Curcumin is suggested to possess potent anti-inflammatory, antioxidant, antimicrobial,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].